Payment overview · 2025
General Payments
$455.17
21 reported records · 10 companies
Healthcare provider profile · identity verified
Kristine Crouch, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · HENDERSON, NV · NPI 1699490748
Verified facts
What the public records show
CMS Open Payments records show Kristine Crouch, FNP received $455.17 in general payments during 2025 across 21 reported records.
Novo Nordisk Inc accounted for 23.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Rybelsus.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $108.93 | 23.9% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $82.81 | 18.2% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $62.90 | 13.8% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $57.06 | 12.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $34.23 | 7.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $32.12 | 7.1% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $24.56 | 5.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $22.86 | 5.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.08 | 3.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.62 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $455.17 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $88.79 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $82.81 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $79.83 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $64.24 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $57.06 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $39.64 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $34.23 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $34.23 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $22.86 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.14 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.19 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.19 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.08 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 96 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 34 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 73 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 42 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
34 | 14 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
96 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
34 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
73 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
42 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
96 | 33 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 441 | 162 |
| Losartan Potassium | Losartan Potassium | 259 | 93 |
| Alprazolam | Alprazolam | 255 | 92 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 253 | 71 |
| Amlodipine Besylate | Amlodipine Besylate | 221 | 86 |
| Gabapentin | Gabapentin | 209 | 81 |
| Zolpidem Tartrate | Zolpidem Tartrate | 208 | 68 |
| Levothyroxine Sodium | Levothyroxine Sodium | 196 | 74 |
| Lisinopril | Lisinopril | 164 | 64 |
| Methylprednisolone | Methylprednisolone | 137 | 123 |
| Tramadol Hcl | Tramadol Hcl | 128 | 44 |
| Trazodone Hcl | Trazodone Hcl | 120 | 47 |
| Fluticasone Propionate | Fluticasone Propionate | 119 | 71 |
| Azithromycin | Azithromycin | 117 | 114 |
| Tamsulosin Hcl | Tamsulosin Hcl | 116 | 48 |
| Temazepam | Temazepam | 114 | 37 |
| Omeprazole | Omeprazole | 112 | 42 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 110 | 37 |
| Metformin Hcl | Metformin Hcl | 104 | 44 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 102 | 57 |
| Hydrochlorothiazide | Hydrochlorothiazide | 99 | 35 |
| Eliquis | Apixaban | 96 | 33 |
| Alendronate Sodium | Alendronate Sodium | 94 | 37 |
| Clonazepam | Clonazepam | 94 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 85 | 24 |
| Meloxicam | Meloxicam | 78 | 24 |
| Ibuprofen | Ibuprofen | 75 | 30 |
| Mounjaro | Tirzepatide | 73 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 67 | 44 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 66 | 59 |
| Furosemide | Furosemide | 66 | 28 |
| Fluoxetine Hcl | Fluoxetine Hcl | 65 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 64 | 19 |
| Sertraline Hcl | Sertraline Hcl | 63 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 62 | 52 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 61 | 37 |
| Famotidine | Famotidine | 60 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 56 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 55 | 22 |
| Simvastatin | Simvastatin | 54 | 17 |
| Lorazepam | Lorazepam | 53 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 51 | 20 |
| Buspirone Hcl | Buspirone Hcl | 50 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 49 | 45 |
| Doxycycline Hyclate | Doxycycline Hyclate | 49 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 47 | 18 |
| Potassium Chloride | Potassium Chloride | 47 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 46 | 14 |
| Meclizine Hcl | Meclizine Hcl | 45 | 39 |
| Allopurinol | Allopurinol | 43 | 14 |
| Ozempic | Semaglutide | 42 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | 11 |
| Finasteride | Finasteride | 41 | 13 |
| Montelukast Sodium | Montelukast Sodium | 41 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 39 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 36 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 36 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 36 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 36 | suppressed |
| Carvedilol | Carvedilol | 35 | 14 |
| Diazepam | Diazepam | 34 | 16 |
| Jardiance | Empagliflozin | 34 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 33 | 18 |
| Atenolol | Atenolol | 32 | 12 |
| Ondansetron Odt | Ondansetron | 32 | 25 |
| Spironolactone | Spironolactone | 32 | 13 |
| Metformin Hcl Er | Metformin Hcl | 30 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 27 |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Ezetimibe | Ezetimibe | 25 | 16 |
| Fluconazole | Fluconazole | 25 | 21 |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Rybelsus | Semaglutide | 24 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Cromolyn Sodium | Cromolyn Sodium | 22 | 19 |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Prednisone | Prednisone | 22 | suppressed |
| Cephalexin | Cephalexin | 21 | 19 |
| Methocarbamol | Methocarbamol | 21 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | 12 |
| Clotrimazole | Clotrimazole | 16 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Ibu | Ibuprofen | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 11 |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Primidone | Primidone | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $455.17 · 21 records | Novo Nordisk Inc | Dexcom G6 Transmitter, ELIQUIS, FREESTYLE LIBRE 3, JARDIANCE, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, REPATHA, Rybelsus, The Cologuard Plus Collection Kit, VRAYLAR, Wegovy, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error